首页> 外文期刊>European journal of gastroenterology and hepatology >Noninvasive markers in the assessment and management of autoimmune liver diseases
【24h】

Noninvasive markers in the assessment and management of autoimmune liver diseases

机译:非侵入性标志物在自身免疫性肝病评估和治疗中的作用

获取原文
获取原文并翻译 | 示例
       

摘要

Historically, liver biopsy has been used to determine the etiology of liver disease, the degree of inflammation, the stage of liver fibrosis, and the response to treatments. In the last decade, the advent of noninvasive tests has improved the diagnosis and management of autoimmune liver diseases. For example, serum markers can identify hepatic inflammation, whereas ultrasound and MRI can diagnose liver fibrosis. Physicians now have a much larger repertoire of diagnostic tests to assess the liver parenchyma compared with liver biopsy alone. In some rare cases, noninvasive tests may provide an alternative to liver biopsy. In general, however, these noninvasive tests complement liver biopsy and provide quick, accurate, and reliable adjunctive data.
机译:从历史上看,肝活检已用于确定肝病的病因,炎症程度,肝纤维化的阶段以及对治疗的反应。在过去的十年中,无创检测技术的出现改善了自身免疫性肝病的诊断和管理。例如,血清标志物可以识别肝炎,而超声和MRI可以诊断肝纤维化。与仅进行肝活检相比,医师现在拥有更多的诊断测试来评估肝实质。在极少数情况下,非侵入性检查可能会替代肝活检。但是,一般而言,这些无创性检查可补充肝活检并提供快速,准确和可靠的辅助数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号